Therapeutic Asset Ratings

308 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
mq719 Melanoma	Memorial Sloan Kettering Cancer Center	P1	C (37)
mt-8421 Melanoma	Molecular Templates, Inc.	P1	C (37)
Naptumomab Estafenatox Melanoma	NeoTX Therapeutics Ltd.	P1	C (37)
ngm438 Melanoma	NGM Biopharmaceuticals, Inc	P1	C (37)
ngm831 Melanoma	NGM Biopharmaceuticals, Inc	P1	C (37)
nm1f Melanoma	Hefei TG ImmunoPharma Co., Ltd.	P1	C (37)
Nst-628 Melanoma	Nested Therapeutics, Inc	P1	C (37)
Optimized Neoantigen Synthetic Long Peptide Vaccine Melanoma	Washington University School of Medicine	P1	C (37)
pf-07263689 Melanoma	Pfizer	P1	C (37)
pf-07329640 Melanoma	Pfizer	P1	C (37)
pf-07799544 Melanoma	Pfizer	P1	C (37)
pf-07820435 Melanoma	Pfizer	P1	C (37)
pf-07921585 Melanoma	Pfizer	P1	C (37)
pf-08046032 Melanoma	Pfizer	P1	C (37)
Proleukin Melanoma	Inge Marie Svane	P1	C (37)
r-5780 Melanoma	Rise Therapeutics LLC	P1	C (37)
RC198 Melanoma	RemeGen Co., Ltd.	P1	C (37)
Second Generation 4-1Bbζ B7H3-Egfrt-Dhfr Melanoma	Seattle Children's Hospital	P1	C (37)
Second Generation 4-1Bbζ Egfr806-Egfrt And A Second Generation 4 1Bbζ Cd19-Her2Tg Melanoma	Seattle Children's Hospital	P1	C (37)
Super1 Tcr-T Melanoma	Guangzhou FineImmune Biotechnology Co., LTD.	P1	C (37)
TASADENOTUREV Melanoma	M.D. Anderson Cancer Center	P1	C (37)
Tbi-1301 Melanoma	University Health Network, Toronto	P1	C (37)
Tetanus Toxoid Melanoma	Duke University	P1	C (37)
Tilt-123 Melanoma	TILT Biotherapeutics Ltd.	P1	C (37)
tqb2618 Melanoma	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	P1	C (37)

Showing 251 to 275 of 308 assets

PreviousPage 11 of 13Next